IMR Press / EJGO / Volume 39 / Issue 5 / DOI: 10.12892/ejgo4011.2018
Open Access Original Research
Feasibility and tolerability of bevacizumab: a retrospective study in Japanese ovarian cancer patients
Show Less
1 Department of Obstetrics and Gynecology, Jichi Medical University, Saitama, Japan
Eur. J. Gynaecol. Oncol. 2018 , 39(5), 790–794; https://doi.org/10.12892/ejgo4011.2018
Published: 10 October 2018
Abstract

Purpose of investigation: To determine the probability of adverse events following bevacizumab (BV) treatment for advanced/recurrent ovarian, fallopian, and peritoneal cancers in Japanese patients. Materials and Methods: The authors retrospectively reviewed medical records of 35 patients. Results: One patient (2.9%) showed a grade 4 gastrointestinal perforation. Grade 1 or 3 gastrointestinal fistula was present in one patient each, whereas one patient had grade 5 tumor hemorrhage. In univariate logistic regression analysis for any grade of gastrointestinal perforation and fistula, the number of prior regimens and period from diagnosis to BV initiation were significant in univariate (p = 0.02 and p = 0.02, respectively) and multivariate (p = 0.02 and p = 0.02, respectively) logistic regression analyses. Conclusions: BV might be tolerable for Japanese patients. In patients where BV is initiated after long periods post-diagnosis or who undergo prior chemotherapy regimens, BV should be used carefully and there should be diligent monitoring for perforations.
Keywords
Ovarian neoplasms
Bevacizumab
Asian Continental Ancestry Group
Intestinal perforation
Chemotherapy
Share
Back to top